Add Company
Join Now

AstriVax Revenue and Competitors

License our Company Data API

Heverlee, BEL

Location

$30M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AstriVax's estimated annual revenue is currently $7.1M per year.(i)
  • AstriVax's estimated revenue per employee is $155,000
  • AstriVax's total funding is $30M.

Employee Data

  • AstriVax has 46 Employees.(i)
  • AstriVax grew their employee count by 5% last year.

AstriVax's People

NameTitleEmail/Phone
1
Chief Business OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.6M4929%N/AN/A
#2
$19.8M128-14%N/AN/A
#3
$249.2M16085%N/AN/A
#4
$28.4M183-19%N/AN/A
#5
$7.1M465%$30.5MN/A
#6
$5M32-9%N/AN/A
#7
$16.6M10745%N/AN/A
#8
$6.7M4348%N/AN/A
#9
$24.2M156-16%N/AN/A
#10
$13.8M8931%N/AN/A
Add Company

What Is AstriVax?

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.

keywords:N/A

$30M

Total Funding

46

Number of Employees

$7.1M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.3M467%N/A
#2
$9M6928%N/A
#3
$9.1M706%N/A
#4
$11.5M7142%N/A
#5
$11.5M74-4%N/A